Lorena de la Peña

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

Alan S. Coates, Eric P. Winer, Aron Goldhirsch et al. · Annals of Oncology · 2015 · 1.8K citations · Full text

Medicine, Oncology, Radiation Oncology +17

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

Antonio Llombart‐Cussac, Javier Cortés, Laia Paré et al. · The Lancet Oncology · 2017 · 341 citations

Medicine, Oncology, Pharmacology +17

<i>PIK3CA</i> Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer

Ian J. Majewski, Paolo Nucíforo, Lorenza Mittempergher et al. · Journal of Clinical Oncology · 2015 · 227 citations · Full text

Medicine, Oncology, Pharmacology +17

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy

Debora Fumagalli, David Venet, Michail Ignatiadis et al. · JAMA Oncology · 2016 · 157 citations · Full text

Medicine, Molecular Medicine, Oncology +17

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer

Mafalda Oliveira, Cristina Saura, Paolo Nucíforo et al. · Annals of Oncology · 2019 · 153 citations · Full text

Medicine, Oncology, Pharmacology +13